Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the overall response rate and disease free survival
for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.